Purpura pigmentosa progressiva unter Immuncheckpoint-Inhibitor-Therapie mit Pembrolizumab

Die Dermatologie 2026 Open access

Read full text
Authors: Annia Cherrez-Eschrich, Amrei Dilling, Kamran Ghoreschi, Alexander Nast
DOI: 10.1007/s00105-026-05657-7
Cited by: 0
References: 4

Abstract

Immune checkpoint inhibitors are now an integral part of cancer treatment, and cutaneous side effects are common. We report the case of a 40-year-old woman who developed purpura pigmentosa progressiva (PPP) in temporal association with pembrolizumab. This case report describes PPP as a rare potential adverse effect of immune checkpoint inhibitors.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Chemotherapy-related skin toxicity Skin Diseases and Diabetes

Publication details

Journal / source
Die Dermatologie
Volume
77
Issue
7
Pages
470–472
Publication date
12 March 2026
Language
DE